Latest News & Features
Big Pharma
Following the UK’s vote to leave the EU, it is business as usual for life sciences companies working with intellectual property, at least for now, says Claire Phipps-Jones of Bristows. 7 July 2016
Big Pharma
The UK’s vote to leave the EU has triggered an immediate need for innovative life sciences companies to evaluate the impact on their patent strategies, argues Laetitia Benard of Allen & Overy. 30 June 2016
Biotechnology
Is it time for healthcare regulators and patent offices to limit the strategies used by existing biologic manufacturers and allow new suppliers to reach some of the world’s most lucrative healthcare systems? Elizabeth Ward of Virtuoso Legal investigates. 30 June 2016
Big Pharma
While pharmaceutical companies are more likely to seek patent protection for their inventions, trade secrets can be useful too, particularly following two recent legislative developments, say Andy Sanderson and Ling Zhuang of Potter Clarkson. 23 June 2016
Americas
The Canadian Intellectual Property Office has updated its guidelines on procedural and examination practices, with some changes affecting biotechnology and medicinal inventions, explain Jason Markwell and Stephanie Anderson of Belmore Neidrauer. 22 June 2016
Asia
In a recent decision in India, biopharma company Biocon and its partner Mylan were allowed to continue marketing a biosimilar breast cancer drug, as Vikrant Rana and Sanjeeta Das of SS Rana report. 16 June 2016
Big Pharma
Ahead of the Life Sciences Law Forum 2016, which takes place on June 23 at Etc Venues in the City of London, LSIPR previews some of the main discussion points. 15 June 2016
Americas
IP and innovation in Mexico has come a long way, and the country’s part in international trade treaties will provide further great opportunities, says Nuria Becerril of Becerril, Coca & Becerril. 10 June 2016
Asia-Pacific
There are clear rules on the use of patient data in clinical trials in Costa Rica, as well as sanctions for any breaches, explain María del Pilar López and Esteban Monge of Zürcher Lawyers. 10 June 2016
Asia
India needs to focus more resources on evaluating applications for biologic drugs, while the biosimilar system needs to be tweaked, says Archana Shanker of Anand and Anand. 9 June 2016